Ticker Details
Denali Therapeutics Inc. Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
IPO Date:	December 8, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.06B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.77 | 2.74%
Avg Daily Range (30 D):	$0.47 | 2.27%
Avg Daily Range (90 D):	$0.53 | 2.71%

Institutional Daily Volume
Avg Daily Volume:	.63M
Avg Daily Volume (30 D):	1.44M
Avg Daily Volume (90 D):	1.38M

Trade Size
Avg Trade Size (Sh.):	69
Avg Trade Size (Sh.) (30 D):	60
Avg Trade Size (Sh.) (90 D):	63

Institutional Trades
Total Institutional Trades:	3,551
Avg Institutional Trade:	$2.75M
Avg Institutional Trade (30 D):	$2.75M
Avg Institutional Trade (90 D):	$2.78M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.84M
Avg Closing Trade (30 D):	$5.72M
Avg Closing Trade (90 D):	$5.1M
Avg Closing Volume:	146.59K

News

Apr 6, 2026 @ 5:26 PM Takeda Exits Dementia Drug Partnership With Denali... Source: Vandana Singh

Apr 1, 2026 @ 12:49 AM The $578 Billion Regenerative Medicine Market Has ... Source: Usa News Group

Feb 5, 2026 @ 7:00 PM Denali Therapeutics Presents Enzyme TransportVehic... Source: Denali Therapeutics Inc.

Jan 29, 2026 @ 9:00 PM Denali Therapeutics Announces Data Presentations o... Source: Na

Dec 30, 2025 @ 1:00 PM The New England Journal of Medicine Publishes Phas... Source: Denali Therapeutics Inc.

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-2.97	$-.73	$-2.97
Diluted EPS	$-2.97	$-.73	$-2.97
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-512.54M	$-128.55M	$-512.54M
Operating Income / Loss	$-555.34M	$-137.37M	$-555.34M
Cost of Revenue
Net Cash Flow	$31.9M	$114.36M	$31.9M
PE Ratio